Biogen Inc. Common Stock (BIIB)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Biogen Inc. Common Stock (BIIB)
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Key Insights
Critical company metrics and information
Share Price
$156.46Market Cap
$22.80 BillionTotal Outstanding Shares
145.72 Million SharesTotal Employees
7,570Dividend
No dividendIPO Date
September 17, 1991SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.biogen.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $-643.30 Million |
Exchange Gains/Losses | $54.60 Million |
Net Cash Flow From Financing Activities | $-1.34 Billion |
Net Cash Flow From Operating Activities | $2.13 Billion |
Net Cash Flow From Investing Activities | $-1.43 Billion |
Net Cash Flow | $-588.70 Million |
Net Cash Flow From Financing Activities, Continuing | $-1.34 Billion |
Net Cash Flow From Operating Activities, Continuing | $2.13 Billion |
Net Cash Flow From Investing Activities, Continuing | $-1.43 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Noncontrolling Interest | $-800,000.00 |
Interest Expense, Operating | $261.80 Million |
Net Income/Loss | $1.61 Billion |
Other Operating Expenses | $3.02 Billion |
Income/Loss From Continuing Operations Before Tax | $1.91 Billion |
Cost Of Revenue | $2.35 Billion |
Operating Income/Loss | $1.91 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Average Shares | $146.10 Million |
Selling, General, and Administrative Expenses | $2.33 Billion |
Operating Expenses | $5.36 Billion |
Costs And Expenses | $7.70 Billion |
Benefits Costs and Expenses | $7.70 Billion |
Income Tax Expense/Benefit | $291.70 Million |
Gross Profit | $7.26 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations After Tax | $1.61 Billion |
Basic Earnings Per Share | $11.11 |
Income Tax Expense/Benefit, Deferred | $-27.80 Million |
Net Income/Loss Attributable To Parent | $1.62 Billion |
Basic Average Shares | $145.50 Million |
Diluted Earnings Per Share | $11.07 |
Net Income/Loss Available To Common Stockholders, Basic | $1.62 Billion |
Revenues | $9.61 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Intangible Assets | $9.81 Billion |
Assets | $28.31 Billion |
Noncurrent Assets | $21.48 Billion |
Liabilities | $11.95 Billion |
Other Non-current Assets | $8.47 Billion |
Current Assets | $6.83 Billion |
Fixed Assets | $3.21 Billion |
Liabilities And Equity | $28.31 Billion |
Current Liabilities | $5.42 Billion |
Other Current Liabilities | $4.71 Billion |
Noncurrent Liabilities | $6.53 Billion |
Accounts Payable | $422.70 Million |
Equity Attributable To Parent | $16.36 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Current Assets | $4.36 Billion |
Wages | $288.70 Million |
Inventory | $2.47 Billion |
Equity | $16.36 Billion |
Long-term Debt | $4.55 Billion |
Other Non-current Liabilities | $1.98 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Biogen Inc. Common Stock (BIIB)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.